Literature DB >> 35372962

Value of Immediate Post-Kidney Biopsy Ultrasound in Excluding Late Hemorrhagic Complications.

Alian Al-Balas1,2, Ammar Almehmi1,2, Michael Allon1.   

Abstract

Background: Hemorrhage is the most serious potential complication of percutaneous kidney biopsy. Patients are typically observed for at least 6-8 hours after a kidney biopsy, with serial measurements of vital signs and hemoglobin to monitor for major hemorrhage. This study assessed whether an immediate postbiopsy ultrasound can reliably exclude delayed major hemorrhage.
Methods: We retrospectively evaluated the clinical outcomes in 147 patients undergoing an outpatient native kidney biopsy with an 18-gauge needle at a large medical center during a 2.5-year period (January 2017 to June 2019). All patients underwent a standardized postbiopsy ultrasound to assess for active extravasation of blood. We extracted from the medical records vital signs and hemoglobin values obtained before the biopsy and at 2, 4, and 6 hours after the procedure. We ascertained whether any patients with a negative postbiopsy ultrasound developed a delayed major hemorrhage.
Results: Each patient underwent two or three biopsy passes. The mean patient age was 48±17 years, 49% were female, 37% were black, 53% had hypertension, and 16% had diabetes. Of the 142 patients without evidence of active extravasation on ultrasound, the BP, heart rate, and hemoglobin remained stable during 6 hours of observation. All were discharged after 6 hours, and none had a late bleeding complication. Conclusions: If the immediate postkidney biopsy ultrasound does not show active bleeding, the patient is extremely unlikely to develop a late major hemorrhagic complication (negative predictive value, 100%). Such patients can be discharged home safely after a 2-hour observation, thereby simplifying their management.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  biopsy; glomerular and tubulointerstitial diseases; hemoglobins; hemorrhage; kidney; outpatients; retrospective studies

Mesh:

Year:  2020        PMID: 35372962      PMCID: PMC8815738          DOI: 10.34067/KID.0002212020

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  9 in total

Review 1.  Bleeding complications of native kidney biopsy: a systematic review and meta-analysis.

Authors:  Kristin M Corapi; Joline L T Chen; Ethan M Balk; Craig E Gordon
Journal:  Am J Kidney Dis       Date:  2012-04-24       Impact factor: 8.860

2.  Safety of outpatient kidney biopsy: one center's experience with 178 native kidney biopsies.

Authors:  Manohar Bairy; Khalid Beleed; Alan T Webb; Sunil Bhandari
Journal:  Am J Kidney Dis       Date:  2008-09       Impact factor: 8.860

3.  A multidisciplinary approach to hemodialysis access: prospective evaluation.

Authors:  M Allon; R Bailey; R Ballard; M H Deierhoi; K Hamrick; R Oser; V K Rhynes; M L Robbin; S Saddekni; S T Zeigler
Journal:  Kidney Int       Date:  1998-02       Impact factor: 10.612

4.  Percutaneous renal biopsy as a day-patient procedure.

Authors:  B F Murphy; A MacIsaac
Journal:  Am J Kidney Dis       Date:  1989-07       Impact factor: 8.860

5.  Timing of complications in percutaneous renal biopsy: what is the optimal period of observation?

Authors:  D S Marwah; S M Korbet
Journal:  Am J Kidney Dis       Date:  1996-07       Impact factor: 8.860

6.  Evaluation of percutaneous renal biopsy as a day case procedure: experience from Nigeria.

Authors:  E Oviasu; P Ugbodaga
Journal:  J Nephrol       Date:  1998 Sep-Oct       Impact factor: 3.902

7.  Percutaneous renal biopsy: outpatient observation without hospitalization is safe.

Authors:  Ivan D Maya; Michael Allon
Journal:  Semin Dial       Date:  2009-05-15       Impact factor: 3.455

8.  Timing of complications in percutaneous renal biopsy.

Authors:  William L Whittier; Stephen M Korbet
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

9.  Renal biopsy as an outpatient procedure.

Authors:  I R Fraser; K F Fairley
Journal:  Am J Kidney Dis       Date:  1995-06       Impact factor: 8.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.